The dynamic landscape of healthcare and managed care pharmacy will be deeply impacted by new and emerging specialty medications. The ever-spiraling costs of specialty medications have led many experts to question whether these treatments translate into true improvements in health outcomes or patients' quality of life.
The dynamic landscape of healthcare and managed care pharmacy will be deeply impacted by new and emerging specialty medications. The ever-spiraling costs of specialty medications have led many experts to question whether these treatments translate into true improvements in health outcomes or patients’ quality of life. However, there are a number of promising agents in the specialty drug pipeline that will play a role in therapy treatments, as well as impact the managed care market.
A specialty drug is one that:
While <1% of patients use specialty drugs, they represents one-fourth of drug spending.
Aimee Tharaldson, PharmD, senior clinical consultant, Express Scripts Holding Company, says there are 3 key specialty market trends for pharmaceuticals: increased competition, rare/orphan drug conditions, and more oral options. Dr Tharaldson suggests there will be an $11.3 billion specialty generic opportunity through 2017 as 38 specialty products’ patents reach expiration, and a $31.8 billion biosimilar opportunity as 51 biologic products reach patent expirations through 2020. Currently, there has also been much incentive for extensive orphan drug development. With 25 million people diagnosed with orphan diseases, the growth rate for orphan drugs is expected to be >25%, while non-orphan drugs are projected at only 20%. The specialty pipeline for orphan drugs shows that they account for 42% of the drugs in development—surpassing the 18% of non-orphan cancer specialty drugs, 16% of inflammatory condition specialty drugs, and far more than any other specialty drugs used to treat hepatitis C, multiple sclerosis (MS), or other orphan diseases.
Dr Tharaldson provided some recent 2013 select orphan drug approvals, which included Ravicti (glycerol phenylbutyrate—Hyperion; oral solution; alternative to Buphenyl) for urea cycle disorders, and Procysbi (cysteamine bitartrate—Raptor; oral; alternative to Cystagon) for nephropathic cystinosis. Select 2013 approvals in cancer included Kadcyla (trastuzumab emtansine—Genentech; IV infusion; antibodyâ€drug conjugate) which is indicated for use in HER2+ advanced/metastatic breast cancer, and Tafinlar/Mekinist (dabrafenib/trametinib — GlaxoSmithKline; oral; BRAF/MEK kinase inhibitor) which is indicated for BRAF V600+ advanced/metastatic melanoma.
In the specialty pipeline, Dr Tharaldson said there are many therapy class drugs that continue to mature. For example, current MS treatment options include immunomodulators like Avonex (interferon betaâ€1a), monoclonal antibodies like Tysabri (natalizumab), and oral therapies like Aubagio (teriflunomide). Pipeline trends suggest MS immunomodulators will improve and go generic (ie, Copaxone; glatiramer acetate—Teva), there will be further monoclonal antibody drug development (ie, Lemtrada; alemtuzumab—Genzyme/Bayer), and there will be increased competition among oral drugs.
Other emerging specialty pipeline therapy class treatments covered by Dr Tharaldson included those for inflammatory conditions, cancer, HIV, hepatitis C, cystic fibrosis, pulmonary arterial hypertension, and bleeding disorders. Some of those pharmaceuticals include blockbuster drugs like Ibrutinib (Pharmacyclics) for leukemia and MCL.
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More